RU95113893A - A NEW COMPOSITION AND ITS SUBCOMPOSITIONS, A METHOD FOR PRODUCING THERE AND A THERAPEUTIC METHOD OF TREATMENT - Google Patents

A NEW COMPOSITION AND ITS SUBCOMPOSITIONS, A METHOD FOR PRODUCING THERE AND A THERAPEUTIC METHOD OF TREATMENT

Info

Publication number
RU95113893A
RU95113893A RU95113893/14A RU95113893A RU95113893A RU 95113893 A RU95113893 A RU 95113893A RU 95113893/14 A RU95113893/14 A RU 95113893/14A RU 95113893 A RU95113893 A RU 95113893A RU 95113893 A RU95113893 A RU 95113893A
Authority
RU
Russia
Prior art keywords
ribofuranose
subcomposition
inflammation
pain
effective amount
Prior art date
Application number
RU95113893/14A
Other languages
Russian (ru)
Inventor
Мария Фуентес Виктория
Original Assignee
Лабораторио Чиле С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лабораторио Чиле С.А. filed Critical Лабораторио Чиле С.А.
Publication of RU95113893A publication Critical patent/RU95113893A/en

Links

Claims (1)

1. Новая композиция и ее субкомпозиция, полученные из растений семейства кактусовых (Cactaceae), и обладающие терапевтическим действием, применяемые при воспалении, боли, зудах различной природы и для регуляции температуры в локальных областях, которые могут быть введены млекопитающим, включая человека, как таковые, или, что более предпочтительно, в виде фармацевтических композиций, содержащих эффективное количество активного ингредиента или ингредиентов, именуемых композицией и/или субкомпозицией, с фармацевтически приемлемым носителем или инертным разбавителем, причем указанная композиция и субкомпозиция обладают высокой терапевтической активностью, не вызывают нежелательных побочных эффектов и состоят из смесей ароматических аминов и углеводов, имеющих следующие формулы и структуры:
а) C8H11O2N, (R)-Гидрокси-1-(4-гидроксифенил)-2-аминоэтан, (S)-1-Гидрокси-1-(4-гидроксифенил)-2-аминоэтан, молекулярные структуры:
Figure 00000001

(S)-1-Гидрокси-1-(4-гидроксифенил)-2-аминоэтан (R)-1-Гидрокси-1-(4-гидроксифенил)-2-аминоэтан:
Figure 00000002

b) C6H12O6; D-галактоза; α- L-галактопираноза; α- D-галактопираноза; β- L-галактофураноза; β- D-галактофураноза; L-галактоза; β- L-галактопираноза; α- L-галактопираноза; α- D-галактофураноза; α- L-галактофураноза, молекулярные структуры:
c) C6H12O6; D-манноза; α- D-маннопираноза; β- D-маннопираноза; α- D-маннофураноза; β- D-маннофураноза; L-манноза; α- L-маннопираноза; β- L-маннопираноза; α- L-маннофураноза; β- L-маннофураноза, молекулярные структуры:
d) C5H10O5; D-рибоза; α- D-рибофураноза; β- D-рибофураноза; L-рибоза; α- L-рибофураноза; β- L-рибофураноза, молекулярные структуры:
e) C6H12O6; D-глюкоза; α- D-глюкопираноза; β- D-глюкопираноза; α- D-глюкофураноза; β- D-глюкофураноза; L-глюкоза; α- L-глюкопираноза; β- L-глюкопираноза; α- L-глюкофураноза, β- L-глюкофураноза, молекулярные структуры:
f) C6H12O5; D-фукоза или 6-дезокси-D-галактоза; α- D-фукопираноза или 6-дезокси- α- D-галактопираноза; β- D-фукопираноза или 6-дезокси- β- D-галактопираноза; α- D-фукофураноза или 6-дезокси- β- D-галактофураноза; β- D-фукофураноза или 6-дезокси- β- D-галактофураноза; L-фукоза или 6-дезокси-L-галактоза; α- L-фукопираноза или 6-дезокси- α- L-галактопираноза; α- L-фукопираноза или 6-дезокси- α- L-галактопираноза; β- L-фукофураноза или 6-дезокси- β- L-галактофураноза; β- L-фукофураноза или 6-дезокси- β- L-галактофураноза, молекулярные структуры:
g) C10H18O9; n1-O-( α,β )-DL-рибофуранозил- ( α,β )-DL-рибофураноза, где n1=углерод 1, 2, 3, 5 молекулярные структуры:
Figure 00000003

где
R1 = 1-O- α- D-рибофураноза, R2, R3 и R4 = H
2-O- α- D-рибофураноза, R2, R3 и R4 = H
3-O- α- D-рибофураноза, R2, R3 и R4 = H
5-O- α- D-рибофураноза, R2, R3 и R4 = H
1-O- β- D-рибофураноза, R2, R3 и R4 = H
2-O- β- D-рибофураноза, R2, R3 и R4 = H
3-O- β- D-рибофураноза, R2, R3 и R4 = H
1-O- β- L-рибофураноза, R2, R3 и R4 = H
2-O- β- L-рибофураноза, R2, R3 и R4 = H
3-O- β- L-рибофураноза, R2, R3 и R4 = H
5-O- β- L-рибофураноза, R2, R3 и R4 = H
R2 = 1-O- α- D-рибофураноза, R1, R3 и R4 = H
2-O- α- D-рибофураноза, R1, R3 и R4 = H
3-O- α- D-рибофураноза, R1, R3 и R4 = H
5-O- α- D-рибофураноза, R1, R3 и R4 = H
1-O- β- L-рибофураноза, R1, R3 и R4 = H
2-O- β- L-рибофураноза, R1, R3 и R4 = H
3-O- β- L-рибофураноза, R1, R3 и R4 = H
5-O- β- L-рибофураноза, R1, R3 и R4 = H
1-O- α- L-рибофураноза, R1, R3 и R4 = H
2-O- α- L-рибофураноза, R1, R3 и R4 = H
3-O- α- L-рибофураноза, R1, R3 и R4 = H
5-O- α- L-рибофураноза, R1, R2 и R4 = H
1-O- β- L-рибофураноза, R1, R3 и R4 = H
2-O- β- L-рибофураноза, R1, R3 и R4 = H
3-O- β- L-рибофураноза, R1, R3 и R4 = H
5-O- β- L-рибофураноза, R1, R3 и R4 = H
R3 = 1-O- α- D-рибофураноза, R1, R2 и R4 = H
2-O- α- D-рибофураноза, R1, R2 и R4 = H
3-O- α- D-рибофураноза, R1, R2 и R4 = H
5-O- α- D-рибофураноза, R1, R2 и R4 = H
1-O- β- D-рибофураноза, R1, R2 и R4 = H
2-O- β- D-рибофураноза, R1, R2 и R4 = H
3-O- β- D-рибофураноза, R1, R2 и R4 = H
5-O- β- D-рибофураноза, R1, R2 и R4 = H
1-O- α- L-рибофураноза, R1, R2 и R4 = H
2-O- α- L-рибофураноза, R1, R2 и R4 = H
3-O- α- L-рибофураноза, R1, R2 и R4 = H
5-O- α- L-рибофураноза, R1, R2 и R4 = H
1-O- β- L-рибофураноза, R1, R2 и R4 = H
2-O- β- L-рибофураноза, R1, R2 и R4 = H
3-O- β- L-рибофураноза, R1, R2 и R4 = H
5-O- β- L-рибофураноза, R1, R2 и R4 = H
R4 = 1-O- α- D-рибофураноза, R1, R2 и R4 = H
2-O- α- D-рибофураноза, R1, R2 и R3 = H
3-O- α- D-рибофураноза, R1, R2 и R3 = H
5-O- α- D-рибофураноза, R1, R2 и R3 = H
1-O- β- D-рибофураноза, R1, R2 и R3 = H
2-O- β- D-рибофураноза, R1, R2 и R3 = H
3-O- β- D-рибофураноза, R1, R2 и R3 = H
5-O- β- D-рибофураноза, R1, R2 и R3 = H
1-O- α- L-рибофураноза, R1, R2 и R3 = H
2-O- α- L-рибофураноза, R1, R2 и R3 = H
3-O- α- L-рибофураноза, R1, R2 и R3 = H
5-O- α- L-рибофураноза, R1, R2 и R3 = H
1-O- β- L-рибофураноза, R1, R2 и R3 = H
2-O- β- L-рибофураноза, R1, R2 и R3 = H
3-O- β- L-рибофураноза, R1, R2 и R3 = H
5-O- β- L-рибофураноза, R1, R2 и R3 = H
Figure 00000004

где R1 = 1-O- α- D-рибофураноза, R2, R3 и R4 = H
2-O- α- D-рибофураноза, R2, R3 и R4 = H
3-O- α- D-рибофураноза, R2, R3 и R4 = H
5-O- α- D-рибофураноза, R2, R3 и R4 = H
1-O- β- D-рибофураноза, R2, R3 и R4 = H
2-O- β- D-рибофураноза, R2, R3 и R4 = H
3-O- β- D-рибофураноза, R2, R3 и R4 = H
5-O- β- D-рибофураноза, R2, R3 и R4 = H
1-O- α- L-рибофураноза, R2, R3 и R4 = H
2-O- α- L-рибофураноза, R2, R3 и R4 = H
3-O- α- L-рибофураноза, R2, R3 и R4 = H
5-O- α- L-рибофураноза, R2, R3 и R4 = H
1-O- β- L-рибофураноза, R2, R3 и R4 = H
2-O- β- L-рибофураноза, R2, R3 и R4 = H
3-O- β- L-рибофураноза, R2, R3 и R4 = H
5-O- β- L-рибофураноза, R2, R3 и R4 = H
R2 = 1-O- α- D-рибофураноза, R1, R3 и R4 = H
2-O- α- D-рибофураноза, R1, R2 и R4 = H
3-O- α- D-рибофураноза, R1, R2 и R4 = H
5-O- α- D-рибофураноза, R1, R2 и R4 = H
1-O- β- D-рибофураноза, R1, R3 и R4 = H
2-O- β- D-рибофураноза, R1, R2 и R4 = H
3-O- β- D-рибофураноза, R1, R2 и R4 = H
5-O- β- D-рибофураноза, R1, R2 и R4 = H
1-O- α- L-рибофураноза, R1, R2 и R4 = H
2-O- α- L-рибофураноза, R1, R3 и R4 = H
3-O- α- L-рибофураноза, R1, R2 и R4 = H
5-O- α- L-рибофураноза, R1, R2 и R4 = H
1-O- β- L-рибофураноза, R1, R3 и R4 = H
2-O- β- L-рибофураноза, R1, R3 и R4 = H
3-O- β- L-рибофураноза, R1, R3 и R4 = H
5-O- β- L-рибофураноза, R1, R2 и R4 = H
R3 = 1-O- α- D-рибофураноза, R1, R2 и R4 = H
2-O- α- D-рибофураноза, R1, R2 и R4 = H
3-O- α- D-рибофураноза, R1, R2 и R4 = H
5-O- α- D-рибофураноза, R1, R2 и R4 = H
1-O- β- D-рибофураноза, R1, R2 и R4 = H
2-O- β- D-рибофураноза, R1, R2 и R4 = H
34-O- β- D-рибофураноза, R1, R2 и R4 = H
5-O- β- D-рибофураноза, R1, R2 и R4 = H
1-O- α- L-рибофураноза, R1, R2 и R4 = H
2-O- α- L-рибофураноза, R1, R2 и R4 = H
3-O- α- L-рибофураноза, R1, R2 и R4 = H
5-O- α- L-рибофураноза, R1, R2 и R4 = H
1-O- β- L-рибофураноза, R1, R2 и R4 = H
2-O- β- L-рибофураноза, R1, R2 и R4 = H
3-O- β- L-рибофураноза, R1, R2 и R4 = H
5-O- β- L-рибофураноза, R1, R2 и R4 = H
R4 = 1-O- α- D-рибофураноза, R1, R2 и R4 = H
2-O- α- D-рибофураноза, R1, R2 и R3 = H
3-O- α- D-рибофураноза, R1, R2 и R3 = H
5-O- α- D-рибофураноза, R1, R2 и R3 = H
1-O- β- D-рибофураноза, R1, R2 и R3 = H
2-O- β- D-рибофураноза, R1, R2 и R3 = H
3-O- β- D-рибофураноза, R1, R2 и R3 = H
5-O- β- D-рибофураноза, R1, R2 и R3 = H
1-O- α- L-рибофураноза, R1, R2 и R3 = H
2-O- α- L-рибофураноза, R1, R2 и R3 = H
3-O- α- L-рибофураноза, R1, R2 и R3 = H
5-O- α- L-рибофураноза, R1, R2 и R3 = H
1-O- β- L-рибофураноза, R1, R2 и R3 = H
2-O- β- L-рибофураноза, R1, R2 и R3 = H
3-O- β- L-рибофураноза, R1, R2 и R3 = H
5-O- β- L-рибофураноза, R1, R2 и R3 = H
Figure 00000005

где R1 = 1-O- α- D-рибофураноза, R2, R3 и R4 = H
2-O- α- D-рибофураноза, R2, R3 и R4 = H
3-O- α- D-рибофураноза, R2, R3 и R4 = H
5-O- α- D-рибофураноза, R2, R3 и R4 = H
1-O- β- D-рибофураноза, R2, R3 и R4 = H
2-O- β- D-рибофураноза, R2, R3 и R4 = H
3-O- β- D-рибофураноза, R2, R3 и R4 = H
5-O- β- D-рибофураноза, R2, R3 и R4 = H
1-O- α- L-рибофураноза, R2, R3 и R4 = H
2-O- α- L-рибофураноза, R2, R3 и R4 = H
3-O- α- L-рибофураноза, R2, R3 и R4 = H
5-O- α- L-рибофураноза, R2, R3 и R4 = H
1-O- β- L-рибофураноза, R2, R3 и R4 = H
2-O- β- L-рибофураноза, R2, R3 и R4 = H
3-O- β- L-рибофураноза, R2, R3 и R4 = H
5-O- β- L-рибофураноза, R2, R3 и R4 = H
R2 = 1-O- α- D-рибофураноза, R1, R3 и R4 = H
2-O- α- D-рибофураноза, R1, R3 и R4 = H
3-O- α- D-рибофураноза, R1, R3 и R4 = H
5-O- α- D-рибофураноза, R1, R3 и R4 = H
1-O- β- D-рибофураноза, R1, R3 и R4 = H
2-O- β- D-рибофураноза, R1, R3 и R4 = H
3-O- β- D-рибофураноза, R1, R3 и R4 = H
5-O- β- D-рибофураноза, R1, R3 и R4 = H
1-O- α- L-рибофураноза, R1, R3 и R4 = H
2-O- α- L-рибофураноза, R1, R3 и R4 = H
3-O- α- L-рибофураноза, R1, R3 и R4 = H
5-O- α- L-рибофураноза, R1, R3 и R4 = H
1-O- β- L-рибофураноза, R1, R3 и R4 = H
2-O- β- L-рибофураноза, R1, R3 и R4 = H
3-O- β- L-рибофураноза, R1, R3 и R4 = H
5-O- β- L-рибофураноза, R1, R3 и R4 = H
R3 = 1-O- α- D-рибофураноза, R1, R2 и R4 = H
2-O- α- D-рибофураноза, R1, R2 и R4 = H
3-O- α- D-рибофураноза, R1, R2 и R4 = H
5-O- α- D-рибофураноза, R1, R2 и R4 = H
1-O- β- D-рибофураноза, R1, R2 и R4 = H
2-O- β- D-рибофураноза, R1, R2 и R4 = H
3-O- β- D-рибофураноза, R1, R2 и R4 = H
5-O- β- D-рибофураноза, R1, R2 и R4 = H
1-O- α- L-рибофураноза, R1, R2 и R4 = H
2-O- α- L-рибофураноза, R1, R2 и R4 = H
3-O- α- L-рибофураноза, R1, R2 и R4 = H
5-O- α- L-рибофураноза, R1, R2 и R4 = H
1-O- β- L-рибофураноза, R1, R2 и R4 = H
2-O- β- L-рибофураноза, R1, R2 и R4 = H
3-O- β- L-рибофураноза, R1, R2 и R4 = H
5-O- β- L-рибофураноза, R1, R2 и R4 = H
R4 = 1-O- α- D-рибофураноза, R1, R2 и R3 = H
2-O- α- D-рибофураноза, R1, R2 и R3 = H
3-O- α- D-рибофураноза, R1, R2 и R3 = H
5-O- α- D-рибофураноза, R1, R2 и R3 = H
1-O- β- D-рибофураноза, R1, R2 и R3 = H
2-O- β- D-рибофураноза, R1, R2 и R3 = H
3-O- β- D-рибофураноза, R1, R2 и R3 = H
5-O- β- D-рибофураноза, R1, R2 и R4 = H
1-O- α- L-рибофураноза, R1, R2 и R3 = H
2-O- α- L-рибофураноза, R1, R2 и R3 = H
3-O- α- L-рибофураноза, R1, R2 и R3 = H
5-O- α- L-рибофураноза, R1, R2 и R3 = H
1-O- β- L-рибофураноза, R1, R2 и R3 = H
2-O- β- L-рибофураноза, R1, R2 и R3 = H
3-O- β- L-рибофураноза, R1, R2 и R3 = H
5-O- β- L-рибофураноза, R1, R2 и R3 = H
Figure 00000006

где R1 = 1-O- α- D-рибофураноза, R2, R3 и R4 = H
2-O- α- D-рибофураноза, R2, R3 и R4 = H
3-O- α- D-рибофураноза, R2, R3 и R4 = H
5-O- α- D-рибофураноза, R2, R3 и R4 = H
1-O- β- D-рибофураноза, R2, R3 и R4 = H
2-O- β- D-рибофураноза, R2, R3 и R4 = H
3-O- β- D-рибофураноза, R2, R3 и R4 = H
5-O- β- D-рибофураноза, R2, R3 и R4 = H
1-O- α- L-рибофураноза, R2, R3 и R4 = H
2-O- α- L-рибофураноза, R2, R3 и R4 = H
3-O- α- L-рибофураноза, R2, R3 и R4 = H
5-O- α- L-рибофураноза, R2, R3 и R4 = H
1-O- β- L-рибофураноза, R2, R3 и R4 = H
2-O- β- L-рибофураноза, R2, R3 и R4 = H
3-O- β- L-рибофураноза, R2, R3 и R4 = H
5-O- β- L-рибофураноза, R2, R3 и R4 = H
R2 = 1-O- α- D-рибофураноза, R1, R3 и R4 = H
2-O- α- D-рибофураноза, R1, R3 и R4 = H
3-O- α- D-рибофураноза, R1, R3 и R4 = H
5-O- α- D-рибофураноза, R1, R3 и R4 = H
1-O- β- D-рибофураноза, R1, R3 и R4 = H
2-O- β- D-рибофураноза, R1, R3 и R4 = H
3-O- β- D-рибофураноза, R1, R3 и R4 = H
5-O- β- D-рибофураноза, R1, R3 и R4 = H
1-O- α- L-рибофураноза, R1, R3 и R4 = H
2-O- α- L-рибофураноза, R1, R3 и R4 = H
3-O- α- L-рибофураноза, R1, R3 и R4 = H
5-O- α- L-рибофураноза, R1, R3 и R4 = H
1-O- β- L-рибофураноза, R1, R3 и R4 = H
2-O- β- L-рибофураноза, R1, R3 и R4 = H
3-O- β- L-рибофураноза, R1, R3 и R4 = H
5-O- β- L-рибофураноза, R1, R3 и R4 = H
R3 = 1-O- α- D-рибофураноза, R1, R2 и R4 = H
2-O- α- D-рибофураноза, R1, R2 и R4 = H
3-O- α- D-рибофураноза, R1, R2 и R4 = H
5-O- α- D-рибофураноза, R1, R2 и R4 = H
1-O- β- D-рибофураноза, R1, R2 и R4 = H
2-O- β- D-рибофураноза, R1, R2 и R4 = H
3-O- β- D-рибофураноза, R1, R2 и R4 = H
5-O- β- D-рибофураноза, R1, R2 и R4 = H
1-O- α- L-рибофураноза, R1, R2 и R4 = H
2-O- α- L-рибофураноза, R1, R2 и R4 = H
3-O- α- L-рибофураноза, R1, R2 и R4 = H
5-O- α- L-рибофураноза, R1, R2 и R4 = H
1-O- β- L-рибофураноза, R1, R2 и R4 = H
2-O- β- L-рибофураноза, R1, R2 и R4 = H
3-O- β- L-рибофураноза, R1, R2 и R4 = H
5-O- β- L-рибофураноза, R1, R2 и R4 = H
R4 = 1-O- α- D-рибофураноза, R1, R2 и R4 = H
2-O- α- D-рибофураноза, R1, R2 и R3 = H
3-O- α- D-рибофураноза, R1, R2 и R3 = H
5-O- α- D-рибофураноза, R1, R2 и R3 = H
1-O- β- D-рибофураноза, R1, R2 и R3 = H
2-O- β- D-рибофураноза, R1, R2 и R3 = H
3-O- β- D-рибофураноза, R1, R2 и R3 = H
5-O- β- D-рибофураноза, R1, R2 и R3 = H
1-O- α- L-рибофураноза, R1, R2 и R3 = H
2-O- α- L-рибофураноза, R1, R2 и R3 = H
3-O- α- L-рибофураноза, R1, R2 и R3 = H
5-O- α- L-рибофураноза, R1, R2 и R3 = H
1-O- β- L-рибофураноза, R1, R2 и R3 = H
2-O- β- L-рибофураноза, R1, R2 и R3 = H
3-O- β- L-рибофураноза, R1, R2 и R3 = H
5-O- β- L-рибофураноза, R1, R2 и R3 = H
2. Первая субкомпозиция по п.1, которая получена из композиции и состоит из смеси ароматического амина и углеводов, имеющих формулы: галактоза и все ее пиранозные и фуранозные оптические изомеры и стереоизомеры, D, L, α и β манноза, и все ее пиранозные и фуранозные оптические изомеры и стереоизомеры, D, L, α и β, (RS)-1-Гидрокси-1-(4-гидроксифенил)-2-аминоэтан.1. The new composition and its subcomposition, obtained from plants of the cactus family (Cactaceae), and having a therapeutic effect, used for inflammation, pain, itching of various nature and for regulating the temperature in local areas that can be introduced to mammals, including humans, as such , or, more preferably, in the form of pharmaceutical compositions containing an effective amount of the active ingredient or ingredients, referred to as a composition and / or subcomposition, with a pharmaceutically acceptable carrier or and an inert diluent, and the specified composition and subcomposition have high therapeutic activity, do not cause unwanted side effects and consist of mixtures of aromatic amines and carbohydrates having the following formulas and structures:
a) C 8 H 11 O 2 N, (R) -Hydroxy-1- (4-hydroxyphenyl) -2-aminoethane, (S) -1-Hydroxy-1- (4-hydroxyphenyl) -2-aminoethane, molecular structures :
Figure 00000001

(S) -1-Hydroxy-1- (4-hydroxyphenyl) -2-aminoethane (R) -1-Hydroxy-1- (4-hydroxyphenyl) -2-aminoethane:
Figure 00000002

b) C 6 H 12 O 6 ; D-galactose; α-L-galactopyranose; α-D-galactopyranose; β-L-galactofuranose; β-D-galactofuranose; L-galactose; β-L-galactopyranose; α-L-galactopyranose; α-D-galactofuranose; α-L-galactofuranose, molecular structures:
c) C 6 H 12 O 6 ; D-mannose; α-D-mannopyranose; β-D-mannopyranose; α-D-mannofuranose; β-D-mannofuranose; L-mannose; α-L-mannopyranose; β-L-mannopyranose; α-L-mannofuranose; β-L-mannofuranose, molecular structures:
d) C 5 H 10 O 5 ; D-ribose α-D-ribofuranose; β-D-ribofuranose; L-ribose; α-L-ribofuranose; β-L-ribofuranose, molecular structures:
e) C 6 H 12 O 6 ; D-glucose; α-D-glucopyranose; β-D-glucopyranose; α-D-glucofuranose; β-D-glucofuranose; L-glucose; α-L-glucopyranose; β-L-glucopyranose; α-L-glucofuranose, β-L-glucofuranose, molecular structures:
f) C 6 H 12 O 5 ; D-fucose or 6-deoxy-D-galactose; α-D-fucopyranose or 6-deoxy-α-D-galactopyranose; β-D-fucopyranose or 6-deoxy-β-D-galactopyranose; α-D-fuco-furanose or 6-deoxy-β-D-galactofuranose; β-D-fuco-furanose or 6-deoxy-β-D-galactofuranose; L-fucose or 6-deoxy-L-galactose; α-L-fucopyranose or 6-deoxy-α-L-galactopyranose; α-L-fucopyranose or 6-deoxy-α-L-galactopyranose; β-L-fuco-furanose or 6-deoxy-β-L-galactofuranose; β-L-fuco-furanose or 6-deoxy-β-L-galactofuranose, molecular structures:
g) C 10 H 18 O 9 ; n 1 -O- (α, β) -DL-ribofuranosyl- (α, β) -DL-ribofuranose, where n 1 = carbon 1, 2, 3, 5 molecular structures:
Figure 00000003

Where
R 1 = 1-O- α-D-ribofuranose, R 2 , R 3 and R 4 = H
2-O- α- D-ribofuranose, R 2 , R 3 and R 4 = H
3-O- α- D-ribofuranose, R 2 , R 3 and R 4 = H
5-O- α- D-ribofuranose, R 2 , R 3 and R 4 = H
1-O- β-D-ribofuranose, R 2 , R 3 and R 4 = H
2-O- β-D-ribofuranose, R 2 , R 3 and R 4 = H
3-O- β-D-ribofuranose, R 2 , R 3 and R 4 = H
1-O- β-L-ribofuranose, R 2 , R 3 and R 4 = H
2-O- β-L-ribofuranose, R 2 , R 3 and R 4 = H
3-O- β-L-ribofuranose, R 2 , R 3 and R 4 = H
5-O- β-L-ribofuranose, R 2 , R 3 and R 4 = H
R 2 = 1-O- α-D-ribofuranose, R 1 , R 3 and R 4 = H
2-O- α- D-ribofuranose, R 1 , R 3 and R 4 = H
3-O- α- D-ribofuranose, R 1 , R 3 and R 4 = H
5-O- α- D-ribofuranose, R 1 , R 3 and R 4 = H
1-O- β-L-ribofuranose, R 1 , R 3 and R 4 = H
2-O- β-L-ribofuranose, R 1 , R 3 and R 4 = H
3-O- β-L-ribofuranose, R 1 , R 3 and R 4 = H
5-O- β-L-ribofuranose, R 1 , R 3 and R 4 = H
1-O- α- L-ribofuranose, R 1 , R 3 and R 4 = H
2-O- α- L-ribofuranose, R 1 , R 3 and R 4 = H
3-O- α- L-ribofuranose, R 1 , R 3 and R 4 = H
5-O- α- L-ribofuranose, R 1 , R 2 and R 4 = H
1-O- β-L-ribofuranose, R 1 , R 3 and R 4 = H
2-O- β-L-ribofuranose, R 1 , R 3 and R 4 = H
3-O- β-L-ribofuranose, R 1 , R 3 and R 4 = H
5-O- β-L-ribofuranose, R 1 , R 3 and R 4 = H
R 3 = 1-O- α-D-ribofuranose, R 1 , R 2 and R 4 = H
2-O- α- D-ribofuranose, R 1 , R 2 and R 4 = H
3-O- α- D-ribofuranose, R 1 , R 2 and R 4 = H
5-O- α- D-ribofuranose, R 1 , R 2 and R 4 = H
1-O- β-D-ribofuranose, R 1 , R 2 and R 4 = H
2-O- β-D-ribofuranose, R 1 , R 2 and R 4 = H
3-O- β-D-ribofuranose, R 1 , R 2 and R 4 = H
5-O- β-D-ribofuranose, R 1 , R 2 and R 4 = H
1-O- α- L-ribofuranose, R 1 , R 2 and R 4 = H
2-O- α-L-ribofuranose, R 1 , R 2 and R 4 = H
3-O- α- L-ribofuranose, R 1 , R 2 and R 4 = H
5-O- α- L-ribofuranose, R 1 , R 2 and R 4 = H
1-O- β-L-ribofuranose, R 1 , R 2 and R 4 = H
2-O- β-L-ribofuranose, R 1 , R 2 and R 4 = H
3-O- β-L-ribofuranose, R 1 , R 2 and R 4 = H
5-O- β-L-ribofuranose, R 1 , R 2 and R 4 = H
R 4 = 1-O- α-D-ribofuranose, R 1 , R 2 and R 4 = H
2-O- α- D-ribofuranose, R 1 , R 2 and R 3 = H
3-O- α- D-ribofuranose, R 1 , R 2 and R 3 = H
5-O- α- D-ribofuranose, R 1 , R 2 and R 3 = H
1-O- β-D-ribofuranose, R 1 , R 2 and R 3 = H
2-O- β-D-ribofuranose, R 1 , R 2 and R 3 = H
3-O- β-D-ribofuranose, R 1 , R 2 and R 3 = H
5-O- β-D-ribofuranose, R 1 , R 2 and R 3 = H
1-O- α- L-ribofuranose, R 1 , R 2 and R 3 = H
2-O- α- L-ribofuranose, R 1 , R 2 and R 3 = H
3-O- α- L-ribofuranose, R 1 , R 2 and R 3 = H
5-O- α- L-ribofuranose, R 1 , R 2 and R 3 = H
1-O- β-L-ribofuranose, R 1 , R 2 and R 3 = H
2-O- β-L-ribofuranose, R 1 , R 2 and R 3 = H
3-O- β-L-ribofuranose, R 1 , R 2 and R 3 = H
5-O- β-L-ribofuranose, R 1 , R 2 and R 3 = H
Figure 00000004

where R 1 = 1-O- α-D-ribofuranose, R 2 , R 3 and R 4 = H
2-O- α- D-ribofuranose, R 2 , R 3 and R 4 = H
3-O- α- D-ribofuranose, R 2 , R 3 and R 4 = H
5-O- α- D-ribofuranose, R 2 , R 3 and R 4 = H
1-O- β-D-ribofuranose, R 2 , R 3 and R 4 = H
2-O- β-D-ribofuranose, R 2 , R 3 and R 4 = H
3-O- β-D-ribofuranose, R 2 , R 3 and R 4 = H
5-O- β-D-ribofuranose, R 2 , R 3 and R 4 = H
1-O- α- L-ribofuranose, R 2 , R 3 and R 4 = H
2-O- α- L-ribofuranose, R 2 , R 3 and R 4 = H
3-O- α- L-ribofuranose, R 2 , R 3 and R 4 = H
5-O- α- L-ribofuranose, R 2 , R 3 and R 4 = H
1-O- β-L-ribofuranose, R 2 , R 3 and R 4 = H
2-O- β-L-ribofuranose, R 2 , R 3 and R 4 = H
3-O- β-L-ribofuranose, R 2 , R 3 and R 4 = H
5-O- β-L-ribofuranose, R 2 , R 3 and R 4 = H
R 2 = 1-O- α-D-ribofuranose, R 1 , R 3 and R 4 = H
2-O- α- D-ribofuranose, R 1 , R 2 and R 4 = H
3-O- α- D-ribofuranose, R 1 , R 2 and R 4 = H
5-O- α- D-ribofuranose, R 1 , R 2 and R 4 = H
1-O- β-D-ribofuranose, R 1 , R 3 and R 4 = H
2-O- β-D-ribofuranose, R 1 , R 2 and R 4 = H
3-O- β-D-ribofuranose, R 1 , R 2 and R 4 = H
5-O- β-D-ribofuranose, R 1 , R 2 and R 4 = H
1-O- α- L-ribofuranose, R 1 , R 2 and R 4 = H
2-O- α- L-ribofuranose, R 1 , R 3 and R 4 = H
3-O- α- L-ribofuranose, R 1 , R 2 and R 4 = H
5-O- α- L-ribofuranose, R 1 , R 2 and R 4 = H
1-O- β-L-ribofuranose, R 1 , R 3 and R 4 = H
2-O- β-L-ribofuranose, R 1 , R 3 and R 4 = H
3-O- β-L-ribofuranose, R 1 , R 3 and R 4 = H
5-O- β-L-ribofuranose, R 1 , R 2 and R 4 = H
R 3 = 1-O- α-D-ribofuranose, R 1 , R 2 and R 4 = H
2-O- α- D-ribofuranose, R 1 , R 2 and R 4 = H
3-O- α- D-ribofuranose, R 1 , R 2 and R 4 = H
5-O- α- D-ribofuranose, R 1 , R 2 and R 4 = H
1-O- β-D-ribofuranose, R 1 , R 2 and R 4 = H
2-O- β-D-ribofuranose, R 1 , R 2 and R 4 = H
34-O- β-D-ribofuranose, R 1 , R 2 and R 4 = H
5-O- β-D-ribofuranose, R 1 , R 2 and R 4 = H
1-O- α- L-ribofuranose, R 1 , R 2 and R 4 = H
2-O- α-L-ribofuranose, R 1 , R 2 and R 4 = H
3-O- α- L-ribofuranose, R 1 , R 2 and R 4 = H
5-O- α- L-ribofuranose, R 1 , R 2 and R 4 = H
1-O- β-L-ribofuranose, R 1 , R 2 and R 4 = H
2-O- β-L-ribofuranose, R 1 , R 2 and R 4 = H
3-O- β-L-ribofuranose, R 1 , R 2 and R 4 = H
5-O- β-L-ribofuranose, R 1 , R 2 and R 4 = H
R 4 = 1-O- α-D-ribofuranose, R 1 , R 2 and R 4 = H
2-O- α- D-ribofuranose, R 1 , R 2 and R 3 = H
3-O- α- D-ribofuranose, R 1 , R 2 and R 3 = H
5-O- α- D-ribofuranose, R 1 , R 2 and R 3 = H
1-O- β-D-ribofuranose, R 1 , R 2 and R 3 = H
2-O- β-D-ribofuranose, R 1 , R 2 and R 3 = H
3-O- β-D-ribofuranose, R 1 , R 2 and R 3 = H
5-O- β-D-ribofuranose, R 1 , R 2 and R 3 = H
1-O- α- L-ribofuranose, R 1 , R 2 and R 3 = H
2-O- α- L-ribofuranose, R 1 , R 2 and R 3 = H
3-O- α- L-ribofuranose, R 1 , R 2 and R 3 = H
5-O- α- L-ribofuranose, R 1 , R 2 and R 3 = H
1-O- β-L-ribofuranose, R 1 , R 2 and R 3 = H
2-O- β-L-ribofuranose, R 1 , R 2 and R 3 = H
3-O- β-L-ribofuranose, R 1 , R 2 and R 3 = H
5-O- β-L-ribofuranose, R 1 , R 2 and R 3 = H
Figure 00000005

where R 1 = 1-O- α-D-ribofuranose, R 2 , R 3 and R 4 = H
2-O- α- D-ribofuranose, R 2 , R 3 and R 4 = H
3-O- α- D-ribofuranose, R 2 , R 3 and R 4 = H
5-O- α- D-ribofuranose, R 2 , R 3 and R 4 = H
1-O- β-D-ribofuranose, R 2 , R 3 and R 4 = H
2-O- β-D-ribofuranose, R 2 , R 3 and R 4 = H
3-O- β-D-ribofuranose, R 2 , R 3 and R 4 = H
5-O- β-D-ribofuranose, R 2 , R 3 and R 4 = H
1-O- α- L-ribofuranose, R 2 , R 3 and R 4 = H
2-O- α- L-ribofuranose, R 2 , R 3 and R 4 = H
3-O- α- L-ribofuranose, R 2 , R 3 and R 4 = H
5-O- α- L-ribofuranose, R 2 , R 3 and R 4 = H
1-O- β-L-ribofuranose, R 2 , R 3 and R 4 = H
2-O- β-L-ribofuranose, R 2 , R 3 and R 4 = H
3-O- β-L-ribofuranose, R 2 , R 3 and R 4 = H
5-O- β-L-ribofuranose, R 2 , R 3 and R 4 = H
R 2 = 1-O- α-D-ribofuranose, R 1 , R 3 and R 4 = H
2-O- α- D-ribofuranose, R 1 , R 3 and R 4 = H
3-O- α- D-ribofuranose, R 1 , R 3 and R 4 = H
5-O- α- D-ribofuranose, R 1 , R 3 and R 4 = H
1-O- β-D-ribofuranose, R 1 , R 3 and R 4 = H
2-O- β-D-ribofuranose, R 1 , R 3 and R 4 = H
3-O- β-D-ribofuranose, R 1 , R 3 and R 4 = H
5-O- β-D-ribofuranose, R 1 , R 3 and R 4 = H
1-O- α- L-ribofuranose, R 1 , R 3 and R 4 = H
2-O- α- L-ribofuranose, R 1 , R 3 and R 4 = H
3-O- α- L-ribofuranose, R 1 , R 3 and R 4 = H
5-O- α- L-ribofuranose, R 1 , R 3 and R 4 = H
1-O- β-L-ribofuranose, R 1 , R 3 and R 4 = H
2-O- β-L-ribofuranose, R 1 , R 3 and R 4 = H
3-O- β-L-ribofuranose, R 1 , R 3 and R 4 = H
5-O- β-L-ribofuranose, R 1 , R 3 and R 4 = H
R 3 = 1-O- α-D-ribofuranose, R 1 , R 2 and R 4 = H
2-O- α- D-ribofuranose, R 1 , R 2 and R 4 = H
3-O- α- D-ribofuranose, R 1 , R 2 and R 4 = H
5-O- α- D-ribofuranose, R 1 , R 2 and R 4 = H
1-O- β-D-ribofuranose, R 1 , R 2 and R 4 = H
2-O- β-D-ribofuranose, R 1 , R 2 and R 4 = H
3-O- β-D-ribofuranose, R 1 , R 2 and R 4 = H
5-O- β-D-ribofuranose, R 1 , R 2 and R 4 = H
1-O- α- L-ribofuranose, R 1 , R 2 and R 4 = H
2-O- α-L-ribofuranose, R 1 , R 2 and R 4 = H
3-O- α- L-ribofuranose, R 1 , R 2 and R 4 = H
5-O- α- L-ribofuranose, R 1 , R 2 and R 4 = H
1-O- β-L-ribofuranose, R 1 , R 2 and R 4 = H
2-O- β-L-ribofuranose, R 1 , R 2 and R 4 = H
3-O- β-L-ribofuranose, R 1 , R 2 and R 4 = H
5-O- β-L-ribofuranose, R 1 , R 2 and R 4 = H
R 4 = 1-O- α-D-ribofuranose, R 1 , R 2 and R 3 = H
2-O- α- D-ribofuranose, R 1 , R 2 and R 3 = H
3-O- α- D-ribofuranose, R 1 , R 2 and R 3 = H
5-O- α- D-ribofuranose, R 1 , R 2 and R 3 = H
1-O- β-D-ribofuranose, R 1 , R 2 and R 3 = H
2-O- β-D-ribofuranose, R 1 , R 2 and R 3 = H
3-O- β-D-ribofuranose, R 1 , R 2 and R 3 = H
5-O- β-D-ribofuranose, R 1 , R 2 and R 4 = H
1-O- α- L-ribofuranose, R 1 , R 2 and R 3 = H
2-O- α- L-ribofuranose, R 1 , R 2 and R 3 = H
3-O- α- L-ribofuranose, R 1 , R 2 and R 3 = H
5-O- α- L-ribofuranose, R 1 , R 2 and R 3 = H
1-O- β-L-ribofuranose, R 1 , R 2 and R 3 = H
2-O- β-L-ribofuranose, R 1 , R 2 and R 3 = H
3-O- β-L-ribofuranose, R 1 , R 2 and R 3 = H
5-O- β-L-ribofuranose, R 1 , R 2 and R 3 = H
Figure 00000006

where R 1 = 1-O- α-D-ribofuranose, R 2 , R 3 and R 4 = H
2-O- α- D-ribofuranose, R 2 , R 3 and R 4 = H
3-O- α- D-ribofuranose, R 2 , R 3 and R 4 = H
5-O- α- D-ribofuranose, R 2 , R 3 and R 4 = H
1-O- β-D-ribofuranose, R 2 , R 3 and R 4 = H
2-O- β-D-ribofuranose, R 2 , R 3 and R 4 = H
3-O- β-D-ribofuranose, R 2 , R 3 and R 4 = H
5-O- β-D-ribofuranose, R 2 , R 3 and R 4 = H
1-O- α- L-ribofuranose, R 2 , R 3 and R 4 = H
2-O- α- L-ribofuranose, R 2 , R 3 and R 4 = H
3-O- α- L-ribofuranose, R 2 , R 3 and R 4 = H
5-O- α- L-ribofuranose, R 2 , R 3 and R 4 = H
1-O- β-L-ribofuranose, R 2 , R 3 and R 4 = H
2-O- β-L-ribofuranose, R 2 , R 3 and R 4 = H
3-O- β-L-ribofuranose, R 2 , R 3 and R 4 = H
5-O- β-L-ribofuranose, R 2 , R 3 and R 4 = H
R 2 = 1-O- α-D-ribofuranose, R 1 , R 3 and R 4 = H
2-O- α- D-ribofuranose, R 1 , R 3 and R 4 = H
3-O- α- D-ribofuranose, R 1 , R 3 and R 4 = H
5-O- α- D-ribofuranose, R 1 , R 3 and R 4 = H
1-O- β-D-ribofuranose, R 1 , R 3 and R 4 = H
2-O- β-D-ribofuranose, R 1 , R 3 and R 4 = H
3-O- β-D-ribofuranose, R 1 , R 3 and R 4 = H
5-O- β-D-ribofuranose, R 1 , R 3 and R 4 = H
1-O- α- L-ribofuranose, R 1 , R 3 and R 4 = H
2-O- α- L-ribofuranose, R 1 , R 3 and R 4 = H
3-O- α- L-ribofuranose, R 1 , R 3 and R 4 = H
5-O- α- L-ribofuranose, R 1 , R 3 and R 4 = H
1-O- β-L-ribofuranose, R 1 , R 3 and R 4 = H
2-O- β-L-ribofuranose, R 1 , R 3 and R 4 = H
3-O- β-L-ribofuranose, R 1 , R 3 and R 4 = H
5-O- β-L-ribofuranose, R 1 , R 3 and R 4 = H
R 3 = 1-O- α-D-ribofuranose, R 1 , R 2 and R 4 = H
2-O- α- D-ribofuranose, R 1 , R 2 and R 4 = H
3-O- α- D-ribofuranose, R 1 , R 2 and R 4 = H
5-O- α- D-ribofuranose, R 1 , R 2 and R 4 = H
1-O- β-D-ribofuranose, R 1 , R 2 and R 4 = H
2-O- β-D-ribofuranose, R 1 , R 2 and R 4 = H
3-O- β-D-ribofuranose, R 1 , R 2 and R 4 = H
5-O- β-D-ribofuranose, R 1 , R 2 and R 4 = H
1-O- α- L-ribofuranose, R 1 , R 2 and R 4 = H
2-O- α-L-ribofuranose, R 1 , R 2 and R 4 = H
3-O- α- L-ribofuranose, R 1 , R 2 and R 4 = H
5-O- α- L-ribofuranose, R 1 , R 2 and R 4 = H
1-O- β-L-ribofuranose, R 1 , R 2 and R 4 = H
2-O- β-L-ribofuranose, R 1 , R 2 and R 4 = H
3-O- β-L-ribofuranose, R 1 , R 2 and R 4 = H
5-O- β-L-ribofuranose, R 1 , R 2 and R 4 = H
R 4 = 1-O- α-D-ribofuranose, R 1 , R 2 and R 4 = H
2-O- α- D-ribofuranose, R 1 , R 2 and R 3 = H
3-O- α- D-ribofuranose, R 1 , R 2 and R 3 = H
5-O- α- D-ribofuranose, R 1 , R 2 and R 3 = H
1-O- β-D-ribofuranose, R 1 , R 2 and R 3 = H
2-O- β-D-ribofuranose, R 1 , R 2 and R 3 = H
3-O- β-D-ribofuranose, R 1 , R 2 and R 3 = H
5-O- β-D-ribofuranose, R 1 , R 2 and R 3 = H
1-O- α- L-ribofuranose, R 1 , R 2 and R 3 = H
2-O- α- L-ribofuranose, R 1 , R 2 and R 3 = H
3-O- α- L-ribofuranose, R 1 , R 2 and R 3 = H
5-O- α- L-ribofuranose, R 1 , R 2 and R 3 = H
1-O- β-L-ribofuranose, R 1 , R 2 and R 3 = H
2-O- β-L-ribofuranose, R 1 , R 2 and R 3 = H
3-O- β-L-ribofuranose, R 1 , R 2 and R 3 = H
5-O- β-L-ribofuranose, R 1 , R 2 and R 3 = H
2. The first subcomposition according to claim 1, which is obtained from the composition and consists of a mixture of aromatic amine and carbohydrates having the formula: galactose and all its pyranose and furanose optical isomers and stereoisomers, D, L, α and β mannose, and all of its pyranose and furanose optical isomers and stereoisomers, D, L, α and β, (RS) -1-Hydroxy-1- (4-hydroxyphenyl) -2-aminoethane. 3. Вторая субкомпозиция по п.1, которая получена из композиции и состоит из смеси углеводов, имеющих формулы: Рибоза, и все ее фуранозные оптические изомеры и стереоизомеры, D, L, α и β, Рибофуранозилрибофураноза, и все ее фуранозные стереоизомеры, D, L, α и β.
4. Третья субкомпозиция по п.1, которая получена из композиции и состоит из смеси углеводов, имеющих формулы: Глюкоза, и все ее пиранозные и фуранозные оптические изомеры и стереоизомеры, D, L, α и β.
5. Четвертая субкомпозиция по п.1, которая получена из композиции и состоит из смеси углеводов, имеющих формулы: Фукоза, и все ее пиранозные и фуранозные оптические изомеры и стереоизомеры, D, L, α и β.
6. Композиция по п. 1, которая входит в состав энтерального, парентерального, кожного, глазного, насального, ушного, ректального, вагинального, уретального, трансбукального и фаринготрахеобронхиального фармацевтического препарата для лечения млекопитающих, включая человека, страдающих воспалениями, болями, локальной гипертермией, и/или зудом, и которая включает в себя терапевтически эффективное количество активного начала, называемого композицией, в сочетании с фармацевтически приемлемым носителем или инертным разбавителем.3. The second subcomposition according to claim 1, which is obtained from the composition and consists of a mixture of carbohydrates having the formula: Ribose, and all its furanose optical isomers and stereoisomers, D, L, α and β, Ribofuranosylribofuranose, and all its furanose stereoisomers, D , L, α and β.
4. The third subcomposition according to claim 1, which is obtained from the composition and consists of a mixture of carbohydrates having the formula: Glucose, and all its pyranose and furanose optical isomers and stereoisomers, D, L, α and β.
5. The fourth subcomposition according to claim 1, which is obtained from the composition and consists of a mixture of carbohydrates having the formula: Fucose, and all its pyranose and furanose optical isomers and stereoisomers, D, L, α and β.
6. The composition according to p. 1, which is part of the enteric, parenteral, cutaneous, ophthalmic, nasal, ear, rectal, vaginal, urethal, trans buccal and pharyngotracheobronchial pharmaceutical preparations for the treatment of mammals, including humans, suffering from inflammation, pain, local hyperthermia, and / or pruritus, and which includes a therapeutically effective amount of an active principle, called a composition, in combination with a pharmaceutically acceptable carrier or inert diluent. 7. Первая субкомпозиция по пп.1 и 2, которая входит в состав энтерального, парентерального, кожного, глазного, насального, ушного, ректального, вагинального, уретального, трансбукального и фаринготрахеобронхиального фармацевтического препарата для лечения млекопитающих, включая человека, страдающих воспалениями, болями, локальной гипертермией и/или зудом, и которая включает терапевтически эффективное количество действующего начала, называемого субкомпозицией-1, в сочетании с фармацевтически приемлемым носителем или инертным разбавителем. 7. The first subcomposition according to claims 1 and 2, which is part of the enteric, parenteral, cutaneous, ophthalmic, nasal, ear, rectal, vaginal, urethal, buccal and pharyngotracheobronchial pharmaceutical preparations for the treatment of mammals, including humans, suffering from inflammation, pain, localized hyperthermia and / or pruritus, and which includes a therapeutically effective amount of an active principle, called subcomposition 1, in combination with a pharmaceutically acceptable carrier or inert diluent eat. 8. Вторая субкомпозиция по пп.1 и 3, которая входит в состав энтерального, парентерального, кожного, глазного, насального, ушного, ректального, вагинального, уретального, трансбукального и фаринготрахеобронхиального фармацевтического препарата для лечения млекопитающих, включая человека, страдающих воспалениями, болями, локальной гипертермией и/или зудом, и которая включает терапевтически эффективное количество действующего начала, называемого субкомпозицией-2, в сочетании с фармацевтически приемлемым носителем или инертным разбавителем. 8. The second subcomposition according to claims 1 and 3, which is part of the enteric, parenteral, skin, ocular, nasal, ear, rectal, vaginal, urethal, buccal and pharyngotracheobronchial pharmaceuticals for the treatment of mammals, including humans, suffering from inflammation, pain, localized hyperthermia and / or pruritus, and which includes a therapeutically effective amount of an active principle, called subcomposition-2, in combination with a pharmaceutically acceptable carrier or inert diluent eat. 9. Третья субкомпозиция по пп.1 и 4, которая входит в состав энтерального, парентерального, кожного, глазного, насального, ушного, ректального, вагинального, уретального, трансбукального и фаринготрахеобронхиального фармацевтического препарата для лечения млекопитающих, включая человека, страдающих воспалениями, болями, локальной гипертермией и/или зудом, и которая включает терапевтически эффективное количество действующего начала, называемого субкомпозицией-3, в сочетании с фармацевтически приемлемым носителем или инертным разбавителем. 9. The third subcomposition according to claims 1 and 4, which is part of the enteric, parenteral, skin, ocular, nasal, ear, rectal, vaginal, urethal, buccal and pharyngotracheobronchial pharmaceutical preparations for the treatment of mammals, including humans, suffering from inflammation, pain, localized hyperthermia and / or pruritus, and which includes a therapeutically effective amount of an active principle, called subcomposition 3, in combination with a pharmaceutically acceptable carrier or inert diluent eat. 10. Четвертая субкомпозиция по пп.1 и 5, которая входит в состав энтерального, парентерального, кожного, глазного, ушного, ректального, вагинального, уретального, трансбукального и фаринготрахеобронхиального фармацевтического препарата для лечения млекопитающих, включая человека, страдающих воспалениями, болями, локальной гипертермией и/или зудом, и которая включает терапевтически эффективное количество действующего начала, называемого субкомпозицией-4, в сочетании с фармацевтически приемлемым носителем или инертным разбавителем. 10. The fourth subcomposition according to claims 1 and 5, which is part of the enteric, parenteral, skin, ocular, ear, rectal, vaginal, urethral, buccal and pharyngotracheobronchial pharmaceuticals for the treatment of mammals, including humans, suffering from inflammation, pain, local hyperthermia and / or itching, and which includes a therapeutically effective amount of an active principle called a subcomposition 4 in combination with a pharmaceutically acceptable carrier or an inert diluent. 11. Терапевтический способ лечения млекопитающих, включая человека, страдающих воспалениями, болями, локальной гипертермией, и/или зудом, заключающийся во введении пациенту терапевтически эффективного количества активного начала, называемого композицией или субкомпозицией по п.1. 11. A therapeutic method for treating mammals, including humans, suffering from inflammation, pain, local hyperthermia, and / or pruritus, comprising administering to a patient a therapeutically effective amount of an active principle called a composition or subcomposition according to claim 1. 12. Терапевтический способ лечения млекопитающих, включая человека, страдающих воспалениями, болями, локальной гипертермией и/или зудом по п.11, заключающийся во введении пациенту терапевтически эффективного количества субкомпозиции-1 по п.2. 12. The therapeutic method for treating mammals, including humans, suffering from inflammation, pain, local hyperthermia and / or itching according to claim 11, comprising administering to the patient a therapeutically effective amount of subcomposition-1 according to claim 2. 13. Терапевтический способ лечения млекопитающих, включая человека, страдающих воспалениями, болями, локальной гипертермией и/или зудом, по п. 11, заключающийся во введении пациенту терапевтически эффективного количества субкомпозиций-2 по п.3. 13. The therapeutic method for treating mammals, including humans, suffering from inflammation, pain, local hyperthermia and / or pruritus, according to claim 11, comprising administering to the patient a therapeutically effective amount of subcompositions-2 according to claim 3. 14. Терапевтический способ лечения млекопитающих, включая человека, страдающих воспалениями, болями, локальной гипертермией и/или зудом, по п. 11, заключающийся во введении пациенту терапевтически эффективного количества субкомпозиции-3 по п.4. 14. The therapeutic method for treating mammals, including humans, suffering from inflammation, pain, local hyperthermia and / or itching, according to claim 11, comprising administering to the patient a therapeutically effective amount of subcomposition-3 according to claim 4. 15. Терапевтический способ лечения млекопитающих, включая человека, страдающих воспалениями, болями, локальной гипертермией и/или зудом по п.11, заключающийся во введении пациенту терапевтически эффективного количества субкомпозиции-4 по п.5. 15. The therapeutic method for treating mammals, including humans, suffering from inflammation, pain, local hyperthermia and / or pruritus according to claim 11, comprising administering to the patient a therapeutically effective amount of subcomposition 4 according to claim 5. 16. Способ получения композиции по п.1 из растений семейства кактусовых (Cactaceae), включающий систему продуцирования со стадиями отбора образцов, сбора материала, секции промывания и замораживания, а также систему очистки со стадиями кондиционирования при определенной температуре, растирания, первичного переваривания, кислотно-щелочного переваривания, криоскопической обработки, фильтрации, нейтрализации, флокуляции, центрифугирования, солюбилизации, промывания, лиофилизации и измельчения. 16. The method of obtaining a composition according to claim 1 from plants of the cactus family (Cactaceae), comprising a production system with stages of sampling, collecting material, a washing and freezing section, and a cleaning system with conditioning steps at a certain temperature, grinding, primary digestion, acid - alkaline digestion, cryoscopic processing, filtration, neutralization, flocculation, centrifugation, solubilization, washing, lyophilization and grinding. 17. Способ получения по п.16, который дополнительно включает систему второй стадии очистки, которая предусматривает мацерацию, центрифугирование, фильтрацию, диализ, выделение и лиофилизацию с выделением субкомпозиций по пп.2 - 4 или 5. 17. The production method according to clause 16, which further includes a second stage purification system, which includes maceration, centrifugation, filtration, dialysis, isolation and lyophilization with separation of subcompositions according to claims 2 to 4 or 5.
RU95113893/14A 1994-08-16 1995-08-15 A NEW COMPOSITION AND ITS SUBCOMPOSITIONS, A METHOD FOR PRODUCING THERE AND A THERAPEUTIC METHOD OF TREATMENT RU95113893A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL117694 1994-08-16

Publications (1)

Publication Number Publication Date
RU95113893A true RU95113893A (en) 1998-08-10

Family

ID=

Similar Documents

Publication Publication Date Title
US4735935A (en) Process for preparation of aloe products products, produced thereby and compositions thereof
AU607681B2 (en) Processes for preparation of aloe products, products produced thereby and compositions thereof
US4917890A (en) Processes for preparation of aloe products, products produced thereby and compositions thereof
US4959214A (en) Processes for preparation of aloe products products produced thereby and compositions thereof
DE3227262A1 (en) METHOD FOR PRODUCING TARGET CELL LYSIS FACTOR AND THE USE THEREOF
Vernon-Roberts et al. Effects of gold salts and prednisolone on inflammatory cells. II. Suppression of inflammation and phagocytosis in the rat.
KR960006916A (en) Compositions and subsidiary compositions having anti-inflammatory, analgesic, antipruritic and local antipyretic effects
Fernandez-Gomez et al. Growth inhibition of Trypanosoma cruzi and Leishmania donovani infantum by different snake venoms: preliminary identification of proteins from Cerastes cerastes venom which interact with the parasites
US4435384A (en) Transfer factor composition and skin treatment
US5876762A (en) Process for obtaining medically active fractions from sea cucumbers
Fyfe et al. The effects of silica on lymph nodes and vessels—a possible mechanism in the pathogenesis of non-filarial endemic elephantiasis
JPS5837001A (en) Production of hyaluronic acid
US5925357A (en) Bifurcated method to process aloe whole leaf
DE3418820A1 (en) MEDICINES FOR DIGESTIVE Ulcers
RU95113893A (en) A NEW COMPOSITION AND ITS SUBCOMPOSITIONS, A METHOD FOR PRODUCING THERE AND A THERAPEUTIC METHOD OF TREATMENT
DE3012204A1 (en) ANTIGEN, PROCESS FOR ITS PRODUCTION AND ITS USE
Wolinsky Chemotherapy and pathology of experimental photochromogenic mycobacterial infections
Bull et al. Inhibition of biological synthesis of acetylcholine by triethylcholine
JPS63501221A (en) Method for producing aloe products, products obtained by the method and compositions thereof
RU2041717C1 (en) Biologically active remedy, method for its producing, preparation containing the mentioned remedy and its application method
RU2225716C2 (en) Composition for stimulating synthesis of melanin pigment and method for its preparing
Uehara et al. Lipopolysaccharide-induced inhibition of gastric acid and pepsin secretion in rats
DE69113437T2 (en) Therapeutic agents for diabetic gangrene.
Loots, JM, Loots, GP & Joubert The effect of allantoin on cellular multiplication in degenerating and regenerating nerves
DE2605576B2 (en) Process for isolating the proteases papain, chimopapain, lysozyme and proteinase X from the milk juice of Carica papaya and use of the isolated proteases for the production of sterilized and lyophilized orthopedic, neurosurgical or ophthalmological preparations